These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35336940)

  • 1. Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection.
    Tauzin A; Gendron-Lepage G; Nayrac M; Anand SP; Bourassa C; Medjahed H; Goyette G; Dubé M; Bazin R; Kaufmann DE; Finzi A
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity.
    Bauer G; Struck F; Staschik E; Maile J; Wochinz-Richter K; Motz M; Soutschek E
    J Med Virol; 2022 Nov; 94(11):5294-5303. PubMed ID: 35851961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies.
    Caruso T; Salani F; Catanese S; Pratesi F; Mercinelli C; Motta G; Genovesi V; Bonato A; Sara G; Masi G; Migliorini P
    Int J Clin Oncol; 2023 Mar; 28(3):363-369. PubMed ID: 36689013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination.
    Garcia L; Woudenberg T; Rosado J; Dyer AH; Donnadieu F; Planas D; Bruel T; Schwartz O; Prazuck T; Velay A; Fafi-Kremer S; Batten I; Reddy C; Connolly E; McElheron M; Kennelly SP; Bourke NM; White MT; Pelleau S
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition.
    Limoges MA; Quenum AJI; Chowdhury MMH; Rexhepi F; Namvarpour M; Akbari SA; Rioux-Perreault C; Nandi M; Lucier JF; Lemaire-Paquette S; Premkumar L; Durocher Y; Cantin A; Lévesque S; Dionne IJ; Menendez A; Ilangumaran S; Allard-Chamard H; Piché A; Ramanathan S
    Front Immunol; 2023; 14():1223936. PubMed ID: 37809081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different long-term avidity maturation for IgG anti-spike and anti-nucleocapsid SARS-CoV-2 in hospitalized COVID-19 patients.
    Heireman L; Boelens J; Coorevits L; Verhasselt B; Vandendriessche S; Padalko E
    Acta Clin Belg; 2022 Jun; 77(3):653-657. PubMed ID: 34152944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
    Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M
    Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
    Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
    Front Immunol; 2022; 13():829665. PubMed ID: 35154152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity.
    Takahashi E; Sawabuchi T; Homma T; Fukuda Y; Sagara H; Kinjo T; Fujita K; Suga S; Kimoto T; Sakai S; Kameda K; Kido H
    Viruses; 2023 Jul; 15(8):. PubMed ID: 37632005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies.
    Tani C; Pratesi F; Talarico R; Cardelli C; Caruso T; Di Cianni F; Laurino E; Italiano N; Moretti M; Manca ML; Migliorini P; Mosca M
    RMD Open; 2021 Dec; 7(3):. PubMed ID: 34880126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients.
    Moura AD; da Costa HHM; Correa VA; de S Lima AK; Lindoso JAL; De Gaspari E; Hong MA; Cunha-Junior JP; Prudencio CR
    Sci Rep; 2021 Sep; 11(1):17642. PubMed ID: 34480056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
    Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
    Front Immunol; 2021; 12():614436. PubMed ID: 33790892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2.
    da Costa HHM; Orts DJB; Moura AD; Duarte-Neto AN; Cirqueira CS; Réssio RA; Kanamura CT; Miguita K; Ferreira JE; Santos RTM; Adriani PP; Cunha-Junior JP; Astray RM; Catarino RM; Lancelotti M; Prudencio CR
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.